Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EHMT2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EHMT2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EHMT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EHMT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EHMT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0018027 | Esophagus | HGIN | peptidyl-lysine dimethylation | 10/2587 | 26/18723 | 1.60e-03 | 1.79e-02 | 10 |
GO:00310604 | Esophagus | HGIN | regulation of histone methylation | 19/2587 | 69/18723 | 2.03e-03 | 2.13e-02 | 19 |
GO:19021162 | Esophagus | HGIN | negative regulation of organelle assembly | 13/2587 | 41/18723 | 2.62e-03 | 2.58e-02 | 13 |
GO:00349688 | Esophagus | HGIN | histone lysine methylation | 27/2587 | 115/18723 | 3.51e-03 | 3.24e-02 | 27 |
GO:000926719 | Esophagus | HGIN | cellular response to starvation | 34/2587 | 156/18723 | 4.21e-03 | 3.77e-02 | 34 |
GO:004259418 | Esophagus | HGIN | response to starvation | 41/2587 | 197/18723 | 4.34e-03 | 3.84e-02 | 41 |
GO:00162422 | Esophagus | HGIN | negative regulation of macroautophagy | 11/2587 | 34/18723 | 4.61e-03 | 3.96e-02 | 11 |
GO:20007853 | Esophagus | HGIN | regulation of autophagosome assembly | 12/2587 | 39/18723 | 4.97e-03 | 4.18e-02 | 12 |
GO:00064798 | Esophagus | HGIN | protein methylation | 38/2587 | 181/18723 | 5.05e-03 | 4.22e-02 | 38 |
GO:00082138 | Esophagus | HGIN | protein alkylation | 38/2587 | 181/18723 | 5.05e-03 | 4.22e-02 | 38 |
GO:00180227 | Esophagus | HGIN | peptidyl-lysine methylation | 29/2587 | 131/18723 | 6.22e-03 | 4.95e-02 | 29 |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:005105215 | Esophagus | ESCC | regulation of DNA metabolic process | 232/8552 | 359/18723 | 2.40e-13 | 1.13e-11 | 232 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04211 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa042111 | Colorectum | AD | Longevity regulating pathway | 33/2092 | 89/8465 | 6.15e-03 | 2.68e-02 | 1.71e-02 | 33 |
hsa042112 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
hsa003102 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa042113 | Colorectum | MSS | Longevity regulating pathway | 33/1875 | 89/8465 | 9.33e-04 | 5.58e-03 | 3.42e-03 | 33 |
hsa003103 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
hsa042114 | Colorectum | FAP | Longevity regulating pathway | 27/1404 | 89/8465 | 8.82e-04 | 5.20e-03 | 3.16e-03 | 27 |
hsa042115 | Colorectum | FAP | Longevity regulating pathway | 27/1404 | 89/8465 | 8.82e-04 | 5.20e-03 | 3.16e-03 | 27 |
hsa0421114 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0031010 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa0421115 | Esophagus | ESCC | Longevity regulating pathway | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0031013 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
hsa0031021 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa042118 | Liver | Cirrhotic | Longevity regulating pathway | 37/2530 | 89/8465 | 1.22e-02 | 3.89e-02 | 2.40e-02 | 37 |
hsa0031031 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
hsa0421111 | Liver | Cirrhotic | Longevity regulating pathway | 37/2530 | 89/8465 | 1.22e-02 | 3.89e-02 | 2.40e-02 | 37 |
hsa0031041 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa0421121 | Liver | HCC | Longevity regulating pathway | 61/4020 | 89/8465 | 4.46e-05 | 2.37e-04 | 1.32e-04 | 61 |
hsa0031051 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
hsa0421131 | Liver | HCC | Longevity regulating pathway | 61/4020 | 89/8465 | 4.46e-05 | 2.37e-04 | 1.32e-04 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EHMT2 | SNV | Missense_Mutation | | c.2509N>G | p.Thr837Ala | p.T837A | | protein_coding | tolerated(0.35) | benign(0.055) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EHMT2 | SNV | Missense_Mutation | | c.1972G>A | p.Ala658Thr | p.A658T | | protein_coding | deleterious(0.03) | possibly_damaging(0.621) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
EHMT2 | SNV | Missense_Mutation | novel | c.1651A>T | p.Asn551Tyr | p.N551Y | | protein_coding | deleterious(0) | possibly_damaging(0.76) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EHMT2 | insertion | Frame_Shift_Ins | novel | c.2932_2933insTAACA | p.Glu978ValfsTer10 | p.E978Vfs*10 | | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EHMT2 | insertion | In_Frame_Ins | novel | c.2931_2932insCCCACTGTT | p.Ser977_Glu978insProThrVal | p.S977_E978insPTV | | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EHMT2 | insertion | Frame_Shift_Ins | novel | c.659_660insTGTTGTA | p.Gly221ValfsTer5 | p.G221Vfs*5 | | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EHMT2 | SNV | Missense_Mutation | | c.3496N>C | p.Asp1166His | p.D1166H | | protein_coding | tolerated(0.08) | benign(0.075) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
EHMT2 | SNV | Missense_Mutation | novel | c.2734N>A | p.Asp912Asn | p.D912N | | protein_coding | tolerated(0.06) | benign(0.186) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EHMT2 | SNV | Missense_Mutation | | c.3141N>C | p.Trp1047Cys | p.W1047C | | protein_coding | tolerated(0.05) | possibly_damaging(0.732) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EHMT2 | SNV | Missense_Mutation | | c.2911N>A | p.Glu971Lys | p.E971K | | protein_coding | tolerated(0.33) | benign(0.106) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | LISINOPRIL HYDRATE | LISINOPRIL HYDRATE | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | DYCLONINE | DYCLONINE | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | SJ000114950 | CHEMBL606456 | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | WIN-552122 | WIN-552122 | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | HISTAMINE | HISTAMINE | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | N-(3-METHOXYPHENYL)ANTHRANILIC ACID | CHEMBL1328677 | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | MEDRONIC ACID | MEDRONIC ACID | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | SJ000014858 | CHEMBL591628 | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | TELMISARTAN | TELMISARTAN | |
10919 | EHMT2 | METHYL TRANSFERASE, ENZYME, DRUGGABLE GENOME | | GNF-PF-989 | CHEMBL583150 | |